Molecular pathology in adult gliomas: diagnostic, prognostic, and predictive markers.

Hdl Handle:
http://hdl.handle.net/10147/200266
Title:
Molecular pathology in adult gliomas: diagnostic, prognostic, and predictive markers.
Authors:
Jansen, Michael; Yip, Stephen; Louis, David N
Affiliation:
Pathology Service, Massachusetts General Hospital, Boston, MA 02114, USA.
Citation:
Molecular pathology in adult gliomas: diagnostic, prognostic, and predictive markers. 2010, 9 (7):717-26 Lancet Neurol
Publisher:
Elsevier
Journal:
Lancet neurology
Issue Date:
Jul-2010
URI:
http://hdl.handle.net/10147/200266
DOI:
10.1016/S1474-4422(10)70105-8
PubMed ID:
20610347
Additional Links:
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3079431/pdf/nihms264471.pdf
Abstract:
Over the past 10 years, there has been an increasing use of molecular markers in the assessment and management of adult malignant gliomas. Some molecular signatures are used diagnostically to help pathologists classify tumours, whereas others are used to estimate prognosis for patients. Most crucial, however, are those markers that are used to predict response to certain therapies, thereby directing clinicians to a particular treatment while avoiding other potentially deleterious therapies. Recently, large-scale genome-wide surveys have been used to identify new biomarkers that have been rapidly developed as diagnostic and prognostic tools. Given these developments, the pace of discovery of new molecular assays will quicken to facilitate personalised medicine in the setting of malignant glioma.
Item Type:
Article
Language:
en
MeSH:
Brain Neoplasms; Glioma; Humans; Pathology, Molecular; Tumor Markers, Biological
ISSN:
1474-4465

Full metadata record

DC FieldValue Language
dc.contributor.authorJansen, Michaelen
dc.contributor.authorYip, Stephenen
dc.contributor.authorLouis, David Nen
dc.date.accessioned2012-01-05T12:45:02Z-
dc.date.available2012-01-05T12:45:02Z-
dc.date.issued2010-07-
dc.identifier.citationMolecular pathology in adult gliomas: diagnostic, prognostic, and predictive markers. 2010, 9 (7):717-26 Lancet Neurolen
dc.identifier.issn1474-4465-
dc.identifier.pmid20610347-
dc.identifier.doi10.1016/S1474-4422(10)70105-8-
dc.identifier.urihttp://hdl.handle.net/10147/200266-
dc.description.abstractOver the past 10 years, there has been an increasing use of molecular markers in the assessment and management of adult malignant gliomas. Some molecular signatures are used diagnostically to help pathologists classify tumours, whereas others are used to estimate prognosis for patients. Most crucial, however, are those markers that are used to predict response to certain therapies, thereby directing clinicians to a particular treatment while avoiding other potentially deleterious therapies. Recently, large-scale genome-wide surveys have been used to identify new biomarkers that have been rapidly developed as diagnostic and prognostic tools. Given these developments, the pace of discovery of new molecular assays will quicken to facilitate personalised medicine in the setting of malignant glioma.-
dc.language.isoenen
dc.publisherElsevieren
dc.relation.urlhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC3079431/pdf/nihms264471.pdfen
dc.subject.meshBrain Neoplasms-
dc.subject.meshGlioma-
dc.subject.meshHumans-
dc.subject.meshPathology, Molecular-
dc.subject.meshTumor Markers, Biological-
dc.titleMolecular pathology in adult gliomas: diagnostic, prognostic, and predictive markers.en
dc.typeArticleen
dc.contributor.departmentPathology Service, Massachusetts General Hospital, Boston, MA 02114, USA.en
dc.identifier.journalLancet neurologyen
dc.description.provinceMunster-

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.